Navigation Links
Nucleonics initiates hepatitis B clinical trial with expressed interfering RNA therapeutic
Date:1/11/2008

HORSHAM, PA (January 11, 2008): Nucleonics, Inc., a privately held biotechnology company focused on the development of novel RNA interference (RNAi)-based therapeutics, announced today that the company has begun treating patients in a Phase 1 human safety study of its experimental treatment for chronic Hepatitis B virus (HBV) infection, NUC B1000.

NUC B1000 (http://www.nucleonicsinc.com/products/hepb.html) is an expressed interfering RNA (eiRNA)-based product consisting of a plasmid DNA construct designed to produce four short interfering RNA (siRNA) molecules, formulated with a proprietary cationic-lipid delivery system. Each of the four siRNAs targets a different sequence of the HBV genome, collectively leading to the potential destruction or elimination of all RNA species produced by HBV within an infected cell. The result is a potent antiviral effect designed for efficacy against all HBV genotypes, including drug resistant strains. Additionally, unlike currently available HBV therapeutics, NUCB1000 is designed to specifically reduce viral antigen load in addition to viral titer, thereby reducing the destructive effects of hepatitis and increasing the potential for resolution of viral infection.

Despite the widespread availability of multiple prophylactic vaccines against HBV, chronic HBV infection remains a public health problem around the world that can lead to such serious diseases as cirrhosis, fibrosis and liver cancer in up to one-third of patients, said Principal Investigator, Robert G. Gish, M.D, Medical Director, Liver Transplant Program and Chief, Division of Hepatology and Complex GI, California Pacific Medical Center, San Francisco. Current anti-HBV drug therapies are of limited effectiveness and are not often used in patients with mild to moderate disease due to risks of developing drug resistance. Thus there is significant need for new treatments that can improve
'/>"/>

Contact: Joan Kureczka
JKureczka@comcast.net
415-821-2413
Kureczka/Martin Associates
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Eltrombopag effective for hepatitis C patients with low blood-platelet counts
2. Possible hepatitis C vaccine
3. Who will recover spontaneously from hepatitis C virus infection
4. Clearance of hepatitis C viral infection after liver transplantation
5. New clinical trial results show how personalized medicine will alter treatment of genetic disorders
6. New clinical data shows chromium picolinate improves cognitive function
7. Study of African traditional medicine will begin world-first clinical trial
8. Singulex Teams With Wyeth Pharmaceuticals to Translate Pre-Clinical Biomarker Research Into Clinical Study Design
9. Cleveland Clinic leading clinical program to improve early-stage lung cancer detection
10. Phase 2 of Singapores Biomedical Sciences Initiative gains momentum for clinical research
11. Clinical studies show REMICADE reduces incidence of bowel surgeries in ulcerative colitis patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/11/2014)... N.C. , Dec. 10, 2014  That blood pressure ... quite a while. Hypertension – the medical term for high ... the early 1800s, and the inflatable cuff that,s used in ... doesn,t, however, mean there,s nothing new about hypertension, its triggers ... long-held beliefs about the condition and the best ways to ...
(Date:12/10/2014)... YORK , Dec. 8, 2014 You,ve been ... banking account but can,t remember your password, site key or ... Who was your first grade teacher? Today, ... the app that will finally put an end ... – 1U TM . 1U leverages a user,s ...
(Date:12/10/2014)... N.C. , Dec. 9, 2014  Wake Forest Baptist ... education building for its School of Medicine. Funding for ... larger capital campaign that will be publicly launched next ... be located in the former 60 series R.J. Reynolds ... Innovation Quarter. Construction will begin immediately with plans to ...
Breaking Biology News(10 mins):Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4
... world,s population is at risk of infection by the dengue virus, ... therapy to protect people from the virus could finally be a ... paper published today in the Proceedings of the National Academy ... Cancer Research, present a novel approach to developing a dengue therapy ...
... New York, NY and San Diego Calif. Proteins that ... aberrant signaling drives the wild proliferation of cells that gives ... receptor (EGFR), fuels a wide variety of cancersincluding a highly ... block its signaling tend to work only for a short ...
... by the human papilloma virus (HPV) has tripled since the ... This study discovered a new mechanism by which HPV causes ... that blocks the mechanism;, The findings could lead to ... COLUMBUS, Ohio Researchers have discovered a new mechanism ...
Cached Biology News:Research advances therapy to protect against dengue virus 2Research advances therapy to protect against dengue virus 3A hijacking of healthy cellular circuits 2A hijacking of healthy cellular circuits 3Researchers design drug to restore cell suicide in HPV-related head and neck cancer 2
(Date:12/19/2014)... YORK , Dec. 18, 2014 Relmada ... therapies for the treatment of chronic pain, announced the ... today. "This was a transformational year in ... promising future for our company," said Sergio Traversa ... year, we have executed on key financial, human resource ...
(Date:12/17/2014)... BASKING RIDGE, N.J. (PRWEB) December 17, 2014 ... Ipsen (Euronext: IPN; ADR: IPSEY), ... 120 mg (referred to as Somatuline®) was approved ... for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) ... differentiated, locally advanced or metastatic disease to improve ...
(Date:12/17/2014)... December 17, 2014 Audacity, a leading ... and member of the Huntsworth Health Group, is proud ... executive team. In her role, Gonzales will serve as ... are incredibly honored to welcome a talent of Jamie’s ... CEO, Gaëtan Fraikin. “She is a proven healthcare innovation ...
(Date:12/17/2014)... LEXINGTON, Mass. , Dec. 17, 2014   ... a biopharmaceutical company developing therapeutic products for rare disorders, ... Healthcare Conference being held in San Francisco, ... , President and Chief Executive Officer, will present on ... p.m. EST).  The presentation will be webcast live and ...
Breaking Biology Technology:Relmada Therapeutics Announces Results of Annual Shareholders Meeting 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 4Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 5Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 6Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 7Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 8Audacity Welcomes Healthcare Communications Expert Jamie Gonzales as Senior Vice President of Client Services 2
... United States Catholic Bishops did not waver, and after ... . , , Wisconsin Right to Life , however, is ... stem cells from human embryos that does not destroy embryos, and ... , ,While various objections still remain, could the fact that this ...
... ilwaukee, Wis. - Teresa Esser sees incredible ... as the new director of the Milwaukee-based Silicon ... more of that opportunity realized. , ,While others are ... in Wisconsin, particularly in the tech sector, Esser sees ...
... - Ten years from now, when people sit in ... clarity, they probably won't think much about the people that ... hard at work as movie-goers take in the last reels ... situated in Hollywood. One of them is Jane Durment, CIO ...
Cached Biology Technology:There's a new dynamic in the stem cell debate 2There's a new dynamic in the stem cell debate 3There's a new dynamic in the stem cell debate 4New Silicon Pastures director envisions more home cooking for Wisconsin angels 2New Silicon Pastures director envisions more home cooking for Wisconsin angels 3New Silicon Pastures director envisions more home cooking for Wisconsin angels 4New Silicon Pastures director envisions more home cooking for Wisconsin angels 5New Silicon Pastures director envisions more home cooking for Wisconsin angels 6CIO Leadership Series: Jane Durment, Marcus Corp. 2CIO Leadership Series: Jane Durment, Marcus Corp. 3CIO Leadership Series: Jane Durment, Marcus Corp. 4
... The IDS 25-Hydroxy Vitamin D ... the quantitative determination of 25-hydroxyvitamin D ... in human serum or plasma. Our ... inconvenience of solvent precipitation and centrifugation ...
... agarose suitable for a wide range of ... to Pulsed Field Gel Electrophoresis (PFGE). Due ... limits, Multi ABgarose can effectively separate large ... in turn means reduced band diffusion, a ...
Mouse monoclonal [1.F.1] to Yersinia pestis F1 antigen ( Abpromise for all tested applications). Antigen: Purified F1 antigen of Y. pestis vaccine strain EB....
Rabbit polyclonal to L Kynurenine ( Abpromise for all tested applications). Antigen: Synthetic peptide L Kynurenine conjugated to a protein carrier. Entrez Gene ID: 8942 Swiss Protein ID...
Biology Products: